Switching From Infliximab to Biosimilar in Patients With IBD Switching From Infliximab to Biosimilar in Patients With IBD

Two infliximab biosimilars are currently available for the treatment of inflammatory bowel disease, at a much lower cost than infliximab innovator. Can patients be safely switched?Alimentary Pharmacology & Therapeutics
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news